Natera Company

Natera is a global leader in providing cell-free DNA testing across multiple clinical areas including women's health, organ health, and oncology. Natera offers a full menu of high-quality genetic tests to support the entire spectrum of women’s health needs—from planning a family and prenatal testing to hereditary cancer screening. Natera has implemented the Panorama AI algorithm, which uses advanced probabilistic modeling and AI-based technology, information from more than 2 million DNA tests performed by Natera.


Connections from

Last Funding Type: Post-IPO Equity
Total Funding: 809150000
Last Funding Date: 2022-11-15
Funding Status: IPO
Employee Number: 1001-5000
Estimated Revenue: $500M to $1B
Technology: Pregnancy biomarkers, Biomarkers of Female Cancers
Investors Number: 15
Founded Date: 2004
Headquarters: San Carlos, California, United States
Industry: Women's Longevity